Biosensor firm physIQ has licensed its technology to Johnson & Johnson’s Janssen pharma unit in a multi-year deal, to investigate use of wearable sensors in virtual clinical trials. Janssen will be able to scale up use of Chicago-based physIQ’s biosensors to support both R&D and… Read More »physIQ licenses virtual trial tech to Janssen in multi-year deal
There is limited access to biomarker testing for cancer in Europe, despite the huge potential of the technology to improve outcomes, according to a new report. The report from European Federation of Pharmaceutical Industries and Associations (EFPIA) shows the results of research conducted in 2020… Read More »Limited access to cancer biomarker testing in Europe, report finds
Startups are turning to voice data as they try to develop tools to detect a wide range of diseases. One startup, Vocalis Health, is working with Mayo Clinic to identify voice-based biomarkers for pulmonary hypertension.
Alphabet’s “moonshot” subsidiary X shared that it failed to find a single biomarker for depression and anxiety. But the company still plans to make its research, which included developing portable EEGs, available to the public.